Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
Wed, 28.05.2025
Mynaric AG
MUNICH, May 28, 2025 – Mynaric AG (OTC: MYNAY, MOYFF; ISIN: US62857X1019) (FRA: M0YN; ISIN: DE000A31C305) (the “Company”) announces that the majority of the voting groups at today's discussion and voting meeting (Erörterungs- und Abstimmungstermin) approved the restructuring plan proposed by the Company in accordance with the German Corporate Stabi [ … ]
Wed, 28.05.2025
IKB Funding Trust I
WKN (German Securities Number): 859275
ISIN: DE0008592759
Stock Exchange: Regulated Market, Frankfurt
IKB Funding Trust I: Ad hoc notification according to Art. 17 MAR
Expected termination/redemption of the Trust Preferred Securities issued by IKB Funding Trust I on June 30, 2025
May 28, 2025
Today, IKB Deutsche Industriebank AG, [ … ]
Wed, 28.05.2025
Biotest AG
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)
Change of the Chief Executive Officer (CEO) of Biotest AG
Dreieich, 28 May 2025. The Supervisory Board of Biotest AG today decided on a change of Chief Executive Officer (CEO).
Dr Jörg Schüttrumpf was appointed today as a member of the Managem [ … ]
Wed, 28.05.2025
FamiCord AG
Leipzig, 28 May 2025 – Polski Bank Komórek Macierzystych sp. z o.o., Poland, (“PBKM”), a wholly owned subsidiary of FamiCord AG, has today entered into an agreement with Primecell Advanced Therapy, a.s., Czech Republic, (“Primecell”) to acquire a further 69% of the shares in Národní centrum pupečníkové krve s.r.o., Czech Republic, as well as a furt [ … ]
Wed, 28.05.2025
Reinet Investments SCA
In terms of the Luxembourg laws and regulations, a notification is required where a holding exceeds or falls below a notifiable threshold.
Reinet has been notified on 27 May 2025 by M&G Plc (“M&G”) that M&G’s voting rights attached to shares in Reinet now represent 4.97 per cent of the voting rights in Reinet, falling below the 5 per c [ … ]
Wed, 28.05.2025
Northern Data AG
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Northern Data Group Receives Strategic Interest
Frankfurt am Main – 28 May 2025 – Northern Data AG (ETR: NB2, together with its subsidiaries, the “Group”) today announces that the Group has received expressions of interest from US-listed companies to ente [ … ]
Wed, 28.05.2025
Swiss Life Asset Management AG
Zurich, 28 May 2025
Ad hoc announcement pursuant to Art. 53 LRSwiss Life REF (CH) ESG Swiss Properties: solid returns in the first half of 2024/25
Realised profit of CHF 30.3 million and net income of CHF 27.4 million achieved
Net asset value (NAV) CHF 112.37
No major sales or capital increases planned at present
Swiss Life REF (CH) ESG Swiss P [ … ]
Wed, 28.05.2025
PIERER Mobility AG
Ad hoc notification pursuant to Article 17 Regulation (EU) No 596/2014 (MAR)
Ad hoc announcement pursuant to Art. 53 LR
Wels, May 28, 2025
PIERER Mobility AG: Key financial figures for financial year 2024
No significant deviations from the preliminary financial figures already communicated
Court confirms restructuring plans for KTM compa [ … ]
Tue, 27.05.2025
ams-OSRAM AG
Ad hoc announcement pursuant to Art. 53 Listing Rules of SIX Swiss Exchange
ams OSRAM has published the proposals for the Annual General Meeting 2025
Premstaetten, Austria and Munich, Germany (27 May 2025) -- ams OSRAM (SIX: AMS) has published the resolutions proposed by the Supervisory Board and the Management Board for the Annual General Meet [ … ]
Tue, 27.05.2025
Pentixapharm Holding AG
Ad hoc announcement pursuant to Art. 17 MAR / Section 15 WpHG
Pentixapharm outlines new clinical development strategy
Clinical pipeline to be refocused on theranostic precision oncology opportunities to enhance value proposition of lead assets
The PTF301 diagnostic trial in Marginal Zone Lymphoma (MZL) will be discontinued.
New CXCR4 tria [ … ]